T-One Therapeutics’ goal is to develop more effective therapies to fight cancer and autoimmune diseases.

The break-through novelty resides in the identification of LINE1-transcripts as the first of a new class of immune response inhibitors that regulate T cells exhaustion by controlling their gene expression profiles. These results could revolutionize current immunotherapies with novel RNA-based therapies aimed at awakening T lymphocytes effector response at transcriptional level.

With our experimental approach we aim to produce new drugs for immunotherapy, through the exploitation of antisense oligonucleotides (ASOs), in order to achieve higher patients response rate and also to reduce side effects that have been reported so far, thus improving patients quality of life.